Viatris Pens Aprepitant Settlement Agreement After Kabi Loses Initial Patent Case
Settlement Permits Launches Of Two ANDA Products From June 2032; Kabi Has Appealed Judgment
Viatris will look to introduce generic versions of Heron Therapeutics’ aprepitant brands, Cinvanti and Aponvie, around three years before patent expiry after settling litigation with the originator. Other court cases remain ongoing.
